The Food and Drug Administration last week issued an update on the Class 1 recall of certain Philips Respironics ventilators. According to the update, FDA has asked the company to retain an independent laboratory to determine whether an incorrect silicone-based foam used to repair and replace certain recalled Trilogy Evo ventilators poses a risk to patient safety. Meanwhile, FDA does not recommend that patients who participated in the repair and replace program discontinue use of the product.

In other news, FDA last week named four active pharmaceutical ingredients to a list of compounding ingredients for which 503B outsourcing facilities may qualify for certain exemptions from the Federal Food, Drug, and Cosmetic Act due to critical need.
 
 

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…